Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A Clinical Study of CD19 Chimeric Antigen Receptor T-Cell Therapy for Patients With Refractory Childhood-Onset Systemic Lupus Erythematosus

Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This study is evaluating the safety and potential benefits of CD19 chimeric antigen receptor T-cell (CAR-T) therapy in children and young adults with severe systemic lupus erythematosus (SLE) that began during childhood. The study will include up to 8 participants aged 25 years or younger whose disease remains active despite treatment with multiple immune-suppressing medicines and has affected at least one major organ. CAR-T cells will be made from each participant's own T cells and modified to recognize CD19, a protein found on B cells that contribute to SLE. Participants will receive chemotherapy to reduce existing immune cells, followed by a single intravenous infusion of SNUH-CD19-CAR-T cells. They will be monitored for side effects and changes in disease activity, organ involvement, laboratory findings, and the need for steroids or other immune-suppressing medicines. The main assessment will be performed 1 year after the CAR-T cell infusion.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 25
Healthy Volunteers: f
View:

• Participants must be 25 years of age or younger at the time of SNUH-CD19-CAR-T infusion.

• Participants must have a diagnosis of systemic lupus erythematosus and meet the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology classification criteria for systemic lupus erythematosus.

• Participants must be currently receiving or have previously received at least three of the following therapies, including corticosteroids: hydroxychloroquine, methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine, tacrolimus, rituximab, or belimumab.

• Participants must have involvement of at least one of the following major organ systems:

‣ Kidney: class II-V lupus nephritis confirmed by biopsy or proteinuria greater than 0.5 g/day

⁃ Heart: pericarditis, myocarditis, conduction abnormality, or valvular disease

⁃ Lung: pleuritis, interstitial lung disease, or pulmonary arterial hypertension

⁃ Hematologic system: platelet count below 50,000/μL or hemolytic anemia

• Participants must have uncontrolled active disease, defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 10 or higher.

Locations
Other Locations
Republic of Korea
Seoul National University Hospital
RECRUITING
Seoul
Contact Information
Primary
Hye Ji, CRC
hyeji91@snu.ac.kr
82-10-2957-8895
Time Frame
Start Date: 2026-09-14
Estimated Completion Date: 2028-12
Participants
Target number of participants: 8
Treatments
Experimental: SNUH-CD19-CAR-T Treatment
Participants will receive protocol-defined lymphodepleting chemotherapy followed by a single intravenous infusion of autologous SNUH-CD19-CAR-T cells at a dose of 0.2 to 1.0 × 10\^6 CAR-positive viable T cells/kg.
Related Therapeutic Areas
Sponsors
Leads: Seoul National University Hospital

This content was sourced from clinicaltrials.gov